On April 17, 2026, six insiders at Rapport Therapeutics, Inc. (RAPP) executed sales of company shares totaling approximately $103.06 million. The transactions involved entities associated with Rock Ventures and TRV GP, with each selling 426,005 shares at a price of $40.32 per share.
The aggregate value of these sales amounts to $17.18 million per entity. While individual insider sales can be motivated by various factors such as diversification or tax planning, a coordinated sale by multiple insiders may attract additional scrutiny from market observers.